Breadcrumb

Breadcrumbs

Press Releases

Search Results

Back to Press Releases
Showing 41 - 46 of 46 results.

You searched for : May 2020 to May 2021.

ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer

ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer Download the PDF version of Article May 21, 2020 Designation follows recent U.S. Breakthrough Therapy Designations for...

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small ...

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung Cancer Download the PDF version of Article May 18, 2020 Refer to Designation based on...

Daiichi Sankyo to Present New Preclinical and Translational Research from DXd ADC Portfolio at AACR ...

Daiichi Sankyo to Present New Preclinical and Translational Research from DXd ADC Portfolio at AACR Virtual Annual Meeting II Download the PDF version of Article May 15, 2020 Preclinical and...

Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual Meeting

Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual Meeting Download the PDF version of Article May 13, 2020 Research data from the pivotal phase 2...

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric ...

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric Cancer Download the PDF version of Article May 11, 2020 Designation based on data from pivotal...

Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in Japan for Tr ...

Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in Japan for Treatment of Patients with HER2 Positive Metastatic Gastric Cancer Download the PDF version of...

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...